PTC Therapeutics, Inc.
100 Corporate Court
South Plainfield
New Jersey
07080-2449
United States
Website: http://www.ptcbio.com/
442 articles with PTC Therapeutics, Inc.
-
Biopharma companies wrapped up September and headed into October with plenty of clinical trial news. Here’s a look.
-
Two-Year Data of Evrysdi™ (risdiplam) in Infants with Spinal Muscular Atrophy Demonstrate Continued Improvement of Developmental Milestones
9/28/2020
PTC Therapeutics, Inc. announced that two-year data from Part 1 of the FIREFISH study demonstrated that infants on Evrysdi™ continued to improve and achieve motor milestones.
-
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 25, 2020
9/25/2020
PTC Therapeutics, Inc. announced that on September 21, 2020 it approved non-statutory stock options to purchase an aggregate of 75,670 shares of its common stock and 12,845 restricted stock units, each representing the right to receive one share of its common stock upon vesting, to 22 new employees.
-
PTC Therapeutics to Present at the Jefferies Virtual Gene Therapy/Editing Summit
9/24/2020
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the Jefferies Virtual Gene Therapy/Editing Summit on Thursday, October 1 st at 9:00 a.m. ET . The presentation will be webcast live on the Events and Presentations page under the investor relations section of P
-
PTC Therapeutics Launches PTC PINPOINT - A Genetic Testing Program for Individuals Suspected of Having Neurotransmitter Disorders
9/9/2020
PTC Therapeutics, Inc. (NASDAQ: PTCT) today introduced a new program that provides genetic testing and counseling for people who may have a neurotransmitter disorder, such as aromatic L-amino acid decarboxylase (AADC) deficiency
-
PTC Therapeutics' 2020 STRIVE Awards for Duchenne Muscular Dystrophy Recognize Four Patient Advocacy Organizations
9/8/2020
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the winners of its sixth annual STRIVE Awards grant program for Duchenne muscular dystrophy.
-
PTC Therapeutics to Present at the Cantor Virtual Global Healthcare Conference
9/3/2020
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the Cantor Virtual Global Healthcare Conference on Thursday, September 17 th at 9:20 a.m. ET . The presentation will be webcast live on the Events and Presentations page under the investor relations section of P
-
PTC Therapeutics Announces First Commercial Milestone Payment Following U.S. FDA Approval of Evrysdi™ (risdiplam)
8/26/2020
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company achieved a $20 million milestone payment from Roche under its License and Collaboration Agreement. The milestone payment was triggered by the first commercial sale of Evrysdi™ (risdiplam) in the U.S. Evrysdi™ was approved by the Food and Drug Admini
-
August has been a busy month for the U.S. Food and Drug Administration. The final two weeks are marked by a number of PDUFA dates, although a few of those drugs have already been approved.
-
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 21, 2020
8/21/2020
PTC Therapeutics, Inc. announced that on August 18, 2020 it approved non-statutory stock options to purchase an aggregate of 49,165 shares of its common stock and 14,175 restricted stock units, each representing the right to receive one share of its common stock upon vesting, to five new employees.
-
PTC Announces the Acceptance of the European Marketing Authorization Application for Evrysdi™ (risdiplam) for the Treatment of Spinal Muscular Atrophy
8/17/2020
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the acceptance of the Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for Evrysdi™ (risdiplam) for the treatment of spinal muscular atrophy (SMA).
-
PTC Therapeutics Announces FDA Approval of Evrysdi™ (risdiplam) for the Treatment of Spinal Muscular Atrophy in Adults and Children 2 months and older
8/7/2020
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the U.S. Food and Drug Administration (FDA) has approved Evrysdi™ (risdiplam), the first at-home, orally administered treatment for spinal muscular atrophy (SMA) in adults and children 2 months and older.
-
PTC Therapeutics' Mary Frances Harmon Named One of the Most Inspiring Leaders in Life Sciences by PharmaVOICE Magazine
8/6/2020
PTC Therapeutics, Inc. (NASDAQ: PTCT) is proud to announce that its Senior Vice President of Corporate and Patient Relations, Mary Frances Harmon, has been named to PharmaVOICE magazine's annual list of the most inspiring people in the life sciences industry
-
PTC Therapeutics Reports Second Quarter 2020 Financial Results and Provides a Corporate Update
8/5/2020
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the second quarter ending June 30, 2020.
-
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2020 Financial Results
7/22/2020
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its second quarter 2020 financial results and provide an update on the company's business and outlook on Wednesday, August 5, 2020 at 4:30 p.m. (ET) after the closing of the market. The call can be access
-
PTC Therapeutics to Host Deep Dive Webinar on Splicing Platform
7/21/2020
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it will host the second webinar in its deep dive series discussing its therapeutic platforms and programs on Friday, July 24 at 10:00 am ET .
-
PTC Therapeutics Announces Agreement to Monetize a Portion of the Risdiplam Royalty Stream for $650 Million
7/20/2020
- Strategic partnership with Royalty Pharma plc. enables PTC to strengthen and advance its diversified rare disorders portfolio - - Conference call scheduled for 8:30 am ET -
-
Clinical Catch-Up: July 6-10
7/13/2020
Everybody seems to be back to work after the U.S. 4th of July holiday. Here’s a look at last week’s clinical trial updates. -
PTC Therapeutics Announces First Patient Dosed in Phase 1 Trial for PTC857
7/8/2020
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the first subject in the Phase 1 clinical trial evaluating PTC857 in healthy volunteers has been dosed. PTC857, discovered through PTC's B
-
PTC Therapeutics Announces CHMP Recommendation of Translarna™ (ataluren) Label Update for Non-Ambulatory Patients with Duchenne Muscular Dystrophy
6/29/2020
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended by a majority of votes to re